Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Twice-daily blood thinner without routine monitoring. | Once-daily blood thinner taken with food. |
| Body system | Blood & Clotting | Blood & Clotting |
| Drug class | Direct oral anticoagulants | Direct oral anticoagulants |
| Supply | Prescription only | Prescription only |
| Main uses | Stroke prevention in atrial fibrillation, Deep vein thrombosis and pulmonary embolism, Clot prevention after hip or knee replacement | Stroke prevention in atrial fibrillation, DVT and pulmonary embolism, Clot prevention after joint replacement, Coronary and peripheral artery disease (low dose with aspirin) |
| How it works | Blocks one key clotting protein directly. | Directly blocks the clotting protein factor Xa. |
| Starts working | 3–4 hours | — |
| Half-life | About 12 hours | 5–9 hours (11–13 in older people) |
| Typical adult dose | AF: 5 mg twice a day (2.5 mg if two of: age ≥80, weight ≤60 kg, poor kidney function). Clot treatment: 10 mg twice a day for 7 days, then 5 mg twice a day. | AF: 20 mg once a day with the evening meal (15 mg with reduced kidney function). |
| Forms | Tablet | Tablet, Oral suspension |
| Common side effects | Bruising, Nosebleeds, Heavy periods | Bruising, Nosebleeds, Heavy periods |
| Serious side effects | Major bleeding, Bleeding in the brain (less than with warfarin) | Major bleeding |
| Don't take if | Active major bleeding; Severe liver disease with clotting abnormalities; Mechanical heart valve; Taking strong CYP3A4 and P-gp inhibitors (ketoconazole, ritonavir) without review | Active major bleeding; Liver disease with clotting abnormalities; Mechanical heart valve; Taking strong CYP3A4 and P-gp inhibitors (ketoconazole, ritonavir) without review |
| Alcohol | Best to limit. Alcohol raises bleeding risk. | Best to limit. Alcohol raises bleeding risk. |
| Pregnancy | Usually avoidedNot used in pregnancy; low-molecular-weight heparin is preferred. | Usually avoidedNot used in pregnancy. |
| Breastfeeding | Usually avoidedAvoid. | Usually avoidedAvoid. |
| In use since | 2012 | 2008 |
| Brand names | United States: EliquisUnited Kingdom: EliquisIndia: Eliquis, Apigat | United States: XareltoUnited Kingdom: XareltoIndia: Xarelto, Rivaxa |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H |
| ATC code | B01AF02 | B01AF01 |
Taken together
- MajorApixaban + Rivaroxaban: Double anticoagulation — serious bleeding risk
Two blood thinners together greatly increase the risk of major bleeding.